Inhalable Degradation‐Tunable Hybrid Nanoparticles With Rapid Lysosomal Escape for Dual siRNA Therapy Against NSCLC
Small · 2026-09 · 22 (51)
DOI: 10.1002/smll.74724 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 23.07.2026. Verfasst von Hezhi Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Nanoparticles, RNA, Small Interfering, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Key Applied Basic Research Program of Liaoning Province, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
The efficacy of gene therapy for lung cancer remains constrained by inadequate tumor targeting and insufficient penetration. Compounding this issue, conventional lipid‐based gene vectors face the clinical challenges of instability induced by nebulization shear forces and severe toxicity caused by excessive positive surface charge. Herein, we engineered inhalable rigid polyester shell‐lipid core hybrid nanoparticles (HNPs) capable of passive targeting upon pulmonary delivery, harnessing the complementary advantages of both liposomes and polymer nanoparticles. Systematic screening of shell type and molecular weight revealed a synergistic interplay between acid‐labile rapidly degrading polyesters and lipids that simultaneously enhanced vibrating‐mesh nebulization stability, pulmonary deposition, mucus and tumor penetration, while remarkably enabling rapid and sustained endo/lysosomal escape, thereby safely elevating short‐term transfection efficiency in lung cancer cells and fibroblasts. To overcome the limited efficacy of single‐target therapy, a dual siRNA delivery approach was employed, whereby the TGF‐β pathway was first silenced to remodel the tumor microenvironment and the undruggable mutant KRAS oncogene was subsequently silenced, leading to tumor growth suppression and reduced metastasis. Collectively, a vector–drug dual‐synergy strategy was established that systematically amplifies the therapeutic efficacy of gene therapy against NSCLC. Coupled with microfluidics‐enabled scalable manufacturing and commercial nebulizer‐compatible inhalability, HNPs hold promise for clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
- School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang, China.
- Joint International Research Laboratory of Intelligent Drug Delivery Systems of Ministry of Education, Shenyang Pharmaceutical University, China.
ORCID-Profile: Lu Qin, Shirui Mao
Förderung
- Key Applied Basic Research Program of Liaoning Province
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Doctoral Startup Research Fund of Liaoning Province
- Key Research Funding of Education Department of Liaoning Province
Zitieren
APA
Wang, H., Li, F., Cui, Z., Zhu, R., Yuan, Y., Yue, M., Zhan, X., An, Y., Qin, L., Zhai, Q., Guan, J., Liu, C., Zhang, Y., Zhang, X., & Mao, S. (2026). Inhalable Degradation‐Tunable Hybrid Nanoparticles With Rapid Lysosomal Escape for Dual siRNA Therapy Against NSCLC. Small, 22(51). https://doi.org/10.1002/smll.74724
Vancouver
Wang H, Li F, Cui Z, Zhu R, Yuan Y, Yue M, et al. Inhalable Degradation‐Tunable Hybrid Nanoparticles With Rapid Lysosomal Escape for Dual siRNA Therapy Against NSCLC. Small. 2026;22(51). doi:10.1002/smll.74724
BibTeX
@article{Wang2026,
author = {Wang, Hezhi and Li, Fan and Cui, Zhixiang and Zhu, Renfang and Yuan, Ye and Yue, Mengmeng and Zhan, Xuanguang and An, Yalin and Qin, Lu and Zhai, Qiyao and Guan, Jian and Liu, Chang and Zhang, Yixuan and Zhang, Xin and Mao, Shirui},
title = {Inhalable Degradation‐Tunable Hybrid Nanoparticles With Rapid Lysosomal Escape for Dual siRNA Therapy Against NSCLC},
journal = {Small},
year = {2026},
volume = {22},
number = {51},
doi = {10.1002/smll.74724}
}
EUVIMED